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Background
TAMOXIFEN METABOLISM AND THE IMPACT OF TAMOXIFEN DOSE ON THE LEVEL OF 
THE ACTIVE METABOLITES IN ENDOCRINE SENSITIVE BREAST CANCER PATIENTS
Breast cancer (BC) is the most common cancer in women1,2. 60-70% of newly diagnosed BC have tumours that express estrogen receptor and/or progesterone 
receptor (ER/PR). These patients will be recommended and benefit from endocrine therapy3 .
Tamoxifen is the most widely used hormonal therapy for the treatment and prevention of hormone-dependent beast cancer4. It is considered to be a “prodrug” that 
requires conversion, by cytochrome P450 (CYP) enzymes into its pharmacologically active metabolites, notably endoxifen (Figure 1). 
The clinical response to tamoxifen varies widely among patients and not all women with hormone positive breast cancer benefit from tamoxifen. The identification of 
the determinants of this variability is important, to predict the benefits of tamoxifen to an individual and to rational optimization of endocrine therapy5.
CYP2D6 genotypes have been shown to determine the level of endoxifen and to predict outcome in patients treated with tamoxifen. This prompted to consider a 
potential role for CYP2D6 genotyping in therapeutic decisions. However, a large inter-patient variability in endoxifen levels still subsist even after correcting for 
CYP2D6 status6,7,8.
Endoxifen levels could represent a better surrogate marker of tamoxifen efficacy, as its level depends also on the activity of other cytochromes (CYP3A4/5, 2C9, 
2C19) and drug interacting comedications, as CYP2D6 inhibitors, frequently prescribed to treat tamoxifen-induced hot flashes.
Several studies provided correlation between CYP2D6 genotype/phenotype and tamoxifen metabolism as well as between CYP2D6 genotype and clinical 
outcomes7,8. However, the relationship between endoxifen levels and clinical outcomes has not been evaluated, and the value of monitoring endoxifen plasma 
concentrations has yet to be explored.
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Methods
Plasma levels of tamoxifen and its major metabolites: 
UPLC triple stage tandem mass spectrometry (UPLC–MS/MS) method is 
under development and will be validated according to the FDA 
recommendations (Figure 2).
Pharmacogenomics:
Determination of CYP2D6 genotype (*3, *4, *5, *6 variant alleles), CYP2D6 
phenotype (dextromethorphan test), CYP3A phenotype (midazolam test), and 
other cytochromes involved in the metabolism and drug transport.
Pharmacokinetic Modelling:
Characterisation of population pharmacokinetic profile of tamoxifen and its 
metabolites using classical non-linear mixed effects modelling techniques 
implemented in the NONMEM® software.
Patients inclusion criteria 
• Hormone-sensitive breast cancer patients (defined as >10% estrogen
receptor and/or >10% progesterone receptor positivity by 
immunohistochemistry).
• Patients treated with tamoxifen and eligible for exposure to higher doses.
Study design
• Interventional, open label phase III trial9.
• 100 to 140 patients needed to be enrolled: until at least 10 poor-
metabolizers, 10 intermediate-metabolizers and 20 extensive-metabolizers
(Figure 3).
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Secondary Objectives
Determine how the increase of tamoxifen dose influences the level of its 
major metabolites in the different genotype groups (poor-, intermediate-, and 
extensive-metabolizers) in patients with hormone-sensitive breast cancer. 
• Characterize the population pharmacokinetic profile of tamoxifen and its 
metabolites, together with inter- and intra-patient variability, and quantify the 
influence of genetic and non-genetic factors on drug levels.
• Investigate the role of the other CYPs (CYP3A4, CYP2C19), conjugation 
enzymes, and drug transporters in the pharmacokinetics of tamoxifen, and 
the impact of their polymorphism on drug and metabolites levels.
• Confirm a relation between hot flashes and CYP2D6 genotypes and/or 
active metabolites levels, and evaluate the role of this clinical symptom 
assessment in the monitoring of tamoxifen treatment. 
• Explore the correlation between genotypes/metabolites levels and clinical 
outcomes in terms of tumor relapse. 
• Assess the feasibility, efficacy, and safety of concentration-guided 
adjustment of tamoxifen dosage in CYP2D6 poor metabolizers (PM).
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Figure 2. UPLC-ESI-MS/MS chromatogram of the highest calibration sample containing tamoxifen and its major 
metabolites. Corresponding deuterated analogues are used as internal standards.
Figure 1. Biotransformation of tamoxifen and its metabolites. CYP3A4/5 is the major CYP isoform responsible 
for the formation of N-desmethyltamoxifen, whereas the generation of the more potent metabolites 4-
hydroxytamoxifen and endoxifen (4-hydroxy-N-desmethyl-tamoxifen) are predominantly catalyzed by CYP2D6. 
Other CYP isoforms, including CYP2C19, CYP2C9, and CYP2B6, appear to play less important roles in tamoxifen
metabolism in vitro. Phase II enzymes may also play a role in endoxifen clearance. SULT1A1: sulphotransferase
1A1; UGT: uridine diphosphate glucuronosyltransferase5.
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Figure 3. Study design. Patients receive tamoxifen (20 mg BID) daily for 4 months in the absence of disease 
progression or toxicity. Blood samples are collected for genotyping, phenotyping, and quantification of tamoxifen
and its metabolites. The results of the CYP2D6 genotyping may be communicated to the patients who are PM, at 
the end of the 4 months and the opportunity of alternative endocrine therapy (e.g. Aromatase inhibitors) will be 
discussed.
